JXR

Jinxin Fertility closed up roughly 4% at HKD 2.23 today, supported by profit recovery signals and institutional backing. H1 2026 fertility center net patient visits expanded 9.1%, with BOCOM International recently initiating Buy coverage, signaling market confidence in earnings improvement. However, earnings per share declined 28%-34% year-over-year over the past two quarters, reflecting persistent operational cost pressures. The stock trades 17% above its 52-week low of HKD 1.92 and carries a price-to-book ratio of just 0.6x trading below net asset value, yet remains down 7% year-to-date, suggesting the market is still digesting prior weakness. The sustainability of profit recovery warrants close attention.

Jinxin Fertility rose 2.63% to HKD 2.145 today, supported by recent positive developments. BOCOM International issued a buy rating, while H1 2026 results signal a sharp profit turnaround with NPV growth of 9.1% to 24,169 new patients, indicating recovery in core markets. Q4 revenue grew 1.7% sequentially to HKD 756 million, though year-on-year profit declined 28.64%, the operational improvement and patient expansion provided market support. However, the stock trades 40.58% below its 52-week high of HKD 3.61 and has declined 10.62% year-to-date, with a market cap of HKD 58.0 billion, suggesting it remains at a relatively depressed valuation.

Jinxin Fertility edged up 0.72% to HKD 2.09 today, supported by near-term catalysts and anticipation around mid-term results review. The company scheduled a board meeting on August 17 to assess interim outcomes, while H1 2026 results signal a sharp profit turnaround with strengthening core-market demand — new patient visits rose 9.1% to 24,169, operating revenue grew 3.97% year-over-year, and BOCOM International reiterated a 'Buy' rating recently. However, historical earnings present a headwind: Q4 2025 and Q3 2025 EPS tumbled 29.44% and 33.43% year-over-year respectively, with net profit down over 28% in both quarters, indicating thin underlying profitability. In terms of valuation, the stock has declined 12.92% year-to-date and sits 42.11% below its 52-week high of HKD 3.61, trading near its moving averages with a PB of 0.56 suggesting relative undervaluation, at a market cap of HKD 56.54 billion.

Stock declined around 2% from today's intraday high of HKD 2.125 to close at HKD 2.075, primarily due to profit-taking following recent rebound and weak liquidity environment (daily turnover rate 0.4%). While H1 2026 interim results showed a turnaround to profitability with NPV rising 9.1% to 24,169 and steady growth in IVF and obstetrics services, the market remains cautious about the sustainability of earnings recovery, limiting follow-through buying support. Technically, the stock has broken below both its 20-day (2.176) and 60-day (2.156) moving averages, declining 13.54% year-to-date; valuation metrics show P/B of just 0.55 suggesting undervaluation, though negative P/E of -5.19 indicates the company is still in profit recovery phase. On the positive side, the stock retains 42.52% downside to its 52-week high of HKD 3.61, BOCOM and other institutions have issued buy ratings, and the board's recent review of interim results may provide near-term catalysts.

Jinxin Fertility Group (1951.HK) rose 1.92% to HKD 2.12 today, driven by BOCOM International's 'Buy' rating upgrade and H1 interim results signals indicating recovery momentum. The stock rallied to HKD 2.165 in morning trading (09:56), reflecting market approval of the company's fertility and obstetrics service growth — H1 fresh frozen oocyte count surged 9.1% year-over-year to 24,169, with net profit showing a sharp turnaround. Afternoon trading (from 13:00 onward) saw profit-taking pressure, pulling the stock back from HKD 2.145 to close at HKD 2.120 on turnover of HKD 25.4 million (0.44% daily turnover rate). Valuation-wise, the stock remains 41.27% below its 52-week high of HKD 3.61 and down 11.67% year-to-date, trading well below its 20-day moving average of HKD 2.18; the price-to-book ratio of just 0.57x reflects conservative market pricing. However, recent quarters show EPS declining 29.44% and 33.43% year-over-year despite stable revenue growth, suggesting profitability headwinds persist; the critical question is whether the oocyte volume inflection can translate meaningfully into earnings recovery.